Close up of human eye

Eyescreen, Inc. Receives SBIR Funding to Use Human Eyes for Testing of Eye Disease and Vision Loss, Reducing Reliance on Animal Models.

According to research, over 200 million individuals worldwide suffer from neovascular age-related macular degeneration (AMD), one of the leading causes of vision loss. Despite the urgent need for treatment, most drug developments still rely on animal models to ensure the safety of humans. Animal models, while imperfect, offer a safer and more controllable environment to investigate potential treatments before transitioning to human trials. However, Jordan Allan, CEO of Eyescreen Inc, highlighted "While some drugs will go through animal models first, 90 % of those fail once human trails begin".

This high failure rate is contributed to by the incompatibility animal models hold. Not only do these delay effective treatments but also significantly increase development costs. For example, the need for repeated testing, failed trials, and the reallocation of time and resources toward drugs that ultimately don't succeed in humans.

Why Donated Human Eyes?

Although animal models have been widely used in ocular research, they still show significant drawbacks when compared to human models.

According to Frans Vinberg, Cofounder and Chief Science Officer of Eyescreen, Inc., "Mice don't really have this central structure macula or fovea that we use for the high acuity color vision".

In simpler terms, humans have a special region in the center of the retina called the macula, and within it, the fovea. These regions allow us to see in sharp detail and vibrant color, especially when reading or looking at faces. Mice, a major model for preclinical ophthalmic testing, lack this feature entirely since their eyes are designed towards detecting movement and seeing in the dark.

Recognizing this limitation Vinberg proposed, "maybe we should have some better models and specifically study human central vision."

This idea led to a groundbreaking collaboration with the Utah Lions Eye Bank and Donor Connect. the first to find a method to revive and preserve light responses in the central retina from post-mortem donated human eyes for up to 48 hours, enabling direct drug testing on human retinal tissue.

Simulating Real Disease Conditions

Shifting away from animal models and toward donated human tissue, Eyescreen, Inc. aims to improve the accuracy of early-stage drug testing, reduce unnecessary costs, and minimize animal testing. They hope to create a path for effective treatments of vision loss.

Allen highlighted "We can see light signaling responses in them just as if they were fully functional in a living, breathing human being." This ability gives scientists a rare and valuable opportunity to test how human retinal cells respond to new drugs.

Beyond monitoring light responses, Allen explained, "We can also expose the eye to stress conditions that simulate real disease, like ischemia, which happens in strokes." Ischemia happens when blood flow, oxygen and nutrients are temporarily cut off from part of the eye. Thus, depriving cells of critical resources needed to function and survive.

Vinberg and Allen studied how to restore nutrients and perfusion—a process called reperfusion—which can cause additional damage when oxygen returns to the tissues too quickly. By recreating this cycle on donated human eyes, they can now observe how real human eye tissue responds to extreme stress and evaluate whether certain drugs can protect or repair the retina.

Meet the Founders of Eyescreen, Inc.

For Allen and Vinberg, their work is more than technical innovation—it's a mission driven by gratitude and purpose. They believe Eyescreen's work is a powerful example of how research and human generosity can come together to accelerate life-changing therapies.

Allen expressed his gratitude to the Utah Lions Bank, Organ Procurement Organization, and Donnor Connect, as well as to all families of the loved ones who've passed away, "they've agreed to donate to help us move forward with science to help those in the future. Just what an incredible sacrifice that is."

Frans VinbergFrans is an associate professor at the University of Utah's Moran Eye Center and has over a decade of experience in retinal research. He earned his PhD in biomedical engineering in Finland before moving to the U.S. in 2012.


Jordan AllenJordan is the CEO and Cofounder of Eyescreen, Inc. He earned his Master's degree in Biomedical Engineering at the University of Utah and previously worked in Vinberg's lab.


Securing Funding and Scaling Up

The team recently secured a Small Business Innovation Research (SBIR) grant securing $306K in funding, marking a major milestone. This grant has enabled CEO Jordan Allen to dedicate himself full-time to advancing their technology and has helped accelerate their research towards improving drug development for vision loss.

By taking a leap into commercialization, Eyescreen, Inc. has gained access to new funding opportunities and is accelerating its path to benefiting patients. Through targeted business development and strategic partnerships, the company is transforming innovative research into real-world impact.

Their next phase includes several key goals:

  • Developing new testing assays for ischemia-reperfusion injury and inflammation to demonstrate stronger clinical relevance.
  • Collaborating with other biotech and pharmaceutical companies to co-develop new testing models that benefit the broader scientific community.
  • Working with the FDA to gain recognition of their platform as a validated drug testing method—with the long-term goal of establishing this approach as a national and international standard.

Collaboration Efforts

Eyescreen's journey has been fueled by a network of collaborators and supporters who helped turn their idea into a scalable company. The team works closely with Altitude Lab, a local bio incubator, and credits the Utah Venture Hub for introducing them to the Innosphere Incubator program. These resources have provided lab space, mentorship, and critical early-stage guidance.

The company also acknowledges Jim Hotaling from Utah Venture Hub, who has been instrumental in helping them understand the University's resources and startup support systems. Another key figure is Won Yong Lee, who played a critical role in guiding them through the process of securing SBIR funding. He also supported them by addressing key early-stage questions and expert guidance during the company's initial setup.

"The University ecosystem is incredibly supportive," said Allen. Jokingly, he added, "I have no doubt that without the University's help, I'm not sure where I'd be — maybe somewhere far removed from this field."

The Utah Innovation Center helped fund the startup's early operational costs—like launching a website and establishing professional communication channels. Additionally, Eyescreen, Inc. participated in the Technology Licensing Office (TLO) National Science Foundation's I-Corps program. This program provides startups with essential resources and insights of turning research ideas and technologies into market-ready solutions.

"The I-Corps experience helped us define our value proposition and understand exactly where our platform fits in the drug development pipeline," Allen explained. "We were able to meet with different industry leaders and really refine our strategy."

Now, Eyescreen, Inc. is preparing to present their work to thousands of attendees at the ARVO conference in Salt Lake City this spring. "We have space there, we have an exhibition booth that will be showing off some of this technology and meeting with lots of different industry leaders and scientific leaders in the field," Allen said. The team hopes their early momentum will build lasting partnerships and shift the paradigm of how treatments for blinding diseases are developed.

Learn more about Eyescreen, Inc. here.

Questions?

We support you and your innovation.

Wherever you are on your innovation journey, the Technology Licensing Office is your go-to source to connect you with the U’s innovation ecosystem.

Call 801.581.7792 or send us a message